PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 1, 2001International Journal of Toxicology153 citationsOpen Access

Gender-Based Differences in the Toxicity of Pharmaceuticals—The Food and Drug Administration's Perspective

View Full Paper
MMMargaret A. MillerUniversity of Notre Dame

Key Result

Women experience more serious adverse reactions to therapeutic drugs than men, including a higher risk of drug-induced torsades de pointes due to differences in cardiac repolarization.

PICO

P
Population
Adverse drug reactions
E
Exposure / Comparator
Therapeutic drugs vs Men
O
Primary Outcome
Adverse events

Abstract

Women experience more adverse reactions to treatment with therapeutic drugs than men. Theories proposed to explain this include overdosing, different pharmacokinetics and pharmacodynamics, women are more likely to report adverse events than men, or women take more medications than men. Food and Drug Administration (FDA) Office of Women's Health (OWH) funds research to promote including women in clinical trials and understanding the biology of sex-related differences in the safety of FDA-regulated products. Including women in clinical trials advances the understanding of drug efficacy and safety in women by providing information on drug dosing, pharmacokinetics, and pharmacodynamics. A Baysian statistical analysis of sex differences in adverse events showed that although about the same number of adverse events were reported for men and women, those reported for women were more serious. One example of a sex difference in the toxicity of pharmaceuticals is the drug-induced cardiac arrhythmia, torsades de point. OWH funded studies in animals and humans to investigate the mechanism behind this sex difference. These studies demonstrated that shortening the QT interval increases the risk of developing torsades and that androgens protect against torsades by slowing cardiac repolarization and prolonging the QT interval. Understanding the mechanisms behind other reported sex-related differences in adverse drug effects requires additional research. The preliminary studies conducted to date suggest that this sex-related difference is likely to be a multifactorial problem requiring information from several fields of study. Ideally, individuals at risk for developing an adverse event should be identified prior to therapeutic intervention. The OWH plans to fund more studies to investigate the role of hormonal variations on drug metabolism and drug-drug interactions. Animal and in vitro model systems are needed to fully understand the mechanism of how gender influences drug toxicity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Margaret A. Miller (2001) conducted a review in Adverse drug reactions. Therapeutic drugs vs. Men was evaluated on Adverse events. Women experience more serious adverse reactions to therapeutic drugs than men, including a higher risk of drug-induced torsades de pointes due to differences in cardiac repolarization.

synapsesocial.com/papers/6aa02760dd133cd5dbe624efhttps://doi.org/10.1080/109158101317097728
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Female Gender as a Risk Factor for Drug-Induced Cardiac Arrhythmias: Evaluation of Clinical and Experimental Evidence1998 · 224 citations
  2. 2Role of Na+:Ca2+ Exchange Current in Cs+‐Induced Early Afterdepolarizations in Purkinje Fibers1994 · 81 citations
  3. 3Influence of gender on the pharmacokinetics and pharmacodynamics of drugs.1998 · 73 citations
  4. 4Gender as a Risk Factor for Adverse Events to Medications1995 · 126 citations
  5. 5Sex-Related Differences in Drug Disposition in Man1984 · 168 citations